Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

NCT06955325 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

270

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Icotinib
DRUG: Rezivertinib
DRUG: Ensartinib
DRUG: Benmelstobart

Sponsor

The First Affiliated Hospital of Guangzhou Medical University